Prostate cancer is the most common noncutaneous malignancy in men. It is an excellent target for primary prevention. Vitamin E trials conducted for prevention of prostate cancer have had conflicting results with a lower incidence of prostate cancer in the ATBC trial and a higher incidence in the vitamin E arm of the SELECT trial. Most of the clinical trials with vitamin E have been limited to the alpha-tocopherol isoform alone. An increasing body of evidence suggests, however, that the gamma- and delta-isoforms of tocopherol and tocotrienols are more promising with regard to cancer prevention. This review tries to justify our assertion that the gamma- and delta-isoforms of tocopherol and tocotrienol might be superior as prostate cancer preventers.
| Identifer | oai:union.ndltd.org:ETSU/oai:dc.etsu.edu:etsu-works-16120 |
| Date | 01 February 2013 |
| Creators | Abu-Shahin, Fadi, Stone, William, Ramsauer, Victoria, Krishnan, Koyamangalath |
| Publisher | Digital Commons @ East Tennessee State University |
| Source Sets | East Tennessee State University |
| Detected Language | English |
| Type | text |
| Source | ETSU Faculty Works |
Page generated in 0.0018 seconds